Concentrated injection and infusion solution for intravenous administration
AssigneeSchering Corporation
InventorsUlrich Speck, Gabriele Schuhmann-Giampieri, Peter Muschick, Werner Krause
Life of this patent
Estimating the term…
Abstract
Additives to concentrated injection and infusion solutions that avoid or mitigate acute or delayed hypersensitivity reactions as well as injection and infusion solutions that contain these additives are described.
Claims19
A method to avoid or mitigate delayed hypersensitivity reactions following administration of an X-ray contrast agent, comprising administering to a patient a concentrated injection or infusion solution comprising a contrast agent and, as an additive, a clotting-inhibiting substance at a concentration of 0.1-50 IU/ml.
A method to avoid or mitigate delayed hypersensitivity reactions following administration of an X-ray agent, comprising administering to a patient a concentrated injection or infusion solution comprising a contrast agent and, as an additive, an inhibitor of complement activation at a concentration of 0.01-100 mg/ml, wherein the inhibitor of complement activation is heparin, ε-aminocaproic acid, lysine, arginine, ornithine, cysteine, homocysteine, a peptide, a polypeptide, tryptophan-tyrosine, glutathione, polylysine, polyinosinic acid, suramin, chlorpromazine or mesoporphyrin.
Dependencies are inferred from the claim text.